Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.

[1]  K. Schulz,et al.  20 µg versus >20 µg estrogen combined oral contraceptives for contraception. , 2013, The Cochrane database of systematic reviews.

[2]  C. Verhoeven,et al.  Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β‐estradiol in comparison to levonorgestrel/ethinylestradiol , 2012, Acta obstetricia et gynecologica Scandinavica.

[3]  M. Oettel,et al.  Estrogens and Antiestrogens I , 2012, Handbook of Experimental Pharmacology.

[4]  M. Allena,et al.  Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How? , 2012, Current Pain and Headache Reports.

[5]  D. Grimes,et al.  Combined oral contraceptive pills for treatment of acne. , 2012, The Cochrane database of systematic reviews.

[6]  P. Darney,et al.  Efficacy, Safety, and Tolerability of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate and 17&bgr;-Estradiol: A Randomized Controlled Trial , 2012, Obstetrics and gynecology.

[7]  M. Rantala,et al.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism , 2011, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[8]  R. Luoto,et al.  Hormonal contraception and mental health: results of a population-based study. , 2011, Human reproduction.

[9]  S. Taneepanichskul,et al.  Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen , 2011, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[10]  Myron S. Cohen,et al.  Combined Oral Contraceptives and Antiretroviral PK/PD in Malawian Women: Pharmacokinetics and Pharmacodynamics of a Combined Oral Contraceptive and a Generic Combined Formulation Antiretroviral in Malawi , 2011, Journal of acquired immune deficiency syndromes.

[11]  M. Morrell,et al.  Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs , 2011, Epilepsy & Behavior.

[12]  E. Prossnitz,et al.  The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. , 2011, Vascular pharmacology.

[13]  S. Christin‐Maitre,et al.  Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study. , 2011, Human reproduction.

[14]  A. Mueck,et al.  Nomegestrol acetate, a novel progestogen for oral contraception , 2011, Steroids.

[15]  S. Hernández-Díaz,et al.  Antibiotics and oral contraceptive failure - a case-crossover study. , 2011, Contraception.

[16]  S. Christin‐Maitre,et al.  Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: A double-blind, randomised, dose-finding pilot study , 2011, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[17]  A. Venn,et al.  Oral Contraceptive Use and Bone , 2011, Current osteoporosis reports.

[18]  V. Remones,et al.  Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol , 2011, Thrombosis and Haemostasis.

[19]  A. Mueck,et al.  Hormonal contraception and risk of endometrial cancer: a systematic review. , 2010, Endocrine-related cancer.

[20]  L. Shulman,et al.  50 years of “The Pill”: celebrating a golden anniversary , 2010, Journal of Family Planning and Reproductive Health Care.

[21]  C. Klipping,et al.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol , 2010, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[22]  G. Di Meglio,et al.  Low-dose oral contraceptives in adolescents: how low can you go? , 2010, Journal of pediatric and adolescent gynecology.

[23]  S. Shapiro,et al.  Oral Contraceptives and Venous Thromboembolism , 2010, Journal of Family Planning and Reproductive Health Care.

[24]  Amanda J Lee,et al.  Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study , 2010, BMJ : British Medical Journal.

[25]  L. Wildt,et al.  Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[26]  A. Mueck,et al.  Why use of dienogest for the first contraceptive pill with estradiol? , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[27]  S. Shapiro,et al.  Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies , 2010, Journal of Family Planning and Reproductive Health Care.

[28]  U. Mellinger,et al.  Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. , 2009, Contraception.

[29]  E. Løkkegaard,et al.  Hormonal contraception and risk of venous thromboembolism: national follow-up study , 2009, BMJ : British Medical Journal.

[30]  F R Rosendaal,et al.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study , 2009, BMJ : British Medical Journal.

[31]  D. Mansour.  Qlaira®: a ‘natural’ change of direction , 2009, Journal of Family Planning and Reproductive Health Care.

[32]  X. Lu,et al.  Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta. , 2008, Endocrinology.

[33]  J. Endrikat,et al.  Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. , 2008, Contraception.

[34]  C. Tempfer,et al.  Non-contraceptive benefits of oral contraceptives , 2008, Expert opinion on pharmacotherapy.

[35]  F. Stanczyk,et al.  Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. , 2008, Contraception.

[36]  V. Miller,et al.  Vascular Actions of Estrogens: Functional Implications , 2008, Pharmacological Reviews.

[37]  F. Rosendaal,et al.  Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use , 2008, American journal of hematology.

[38]  M. Vessey,et al.  Oral contraceptives and benign breast disease: an update of findings in a large cohort study. , 2007, Contraception.

[39]  V. Beral,et al.  Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies , 2007, The Lancet.

[40]  Jason Hsia,et al.  Oral Contraceptives and the Risk of Death From Breast Cancer , 2007, Obstetrics and gynecology.

[41]  S. le Cessie,et al.  Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations , 2007, British journal of haematology.

[42]  R. Coates,et al.  Oral Contraceptives and Survival in Breast Cancer Patients Aged 20 to 54 Years , 2007, Cancer Epidemiology Biomarkers & Prevention.

[43]  S. Johansson,et al.  The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. , 2007, Maturitas.

[44]  L. Newby,et al.  Age Moderates the Short-Term Effects of Transdermal 17β-Estradiol on Endothelium-Dependent Vascular Function in Postmenopausal Women , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[45]  L. Heinemann,et al.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. , 2007, Contraception.

[46]  U. Karck,et al.  The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: Results from two studies on oestrogen-related symptoms and dysmenorrhoea , 2007, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[47]  V. Craig Jordan,et al.  International Union of Pharmacology. LXIV. Estrogen Receptors , 2006, Pharmacological Reviews.

[48]  P. Muti,et al.  Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. , 2006, Biochimica et biophysica acta.

[49]  Christina N Lessov-Schlaggar,et al.  Female sex and oral contraceptive use accelerate nicotine metabolism , 2006, Clinical pharmacology and therapeutics.

[50]  M. Phillip,et al.  Endocrine Regulation of the Growth Plate , 2005, Hormone Research in Paediatrics.

[51]  E. Brodtkorb,et al.  Ethinyl Estradiol, Not Progestogens, Reduces Lamotrigine Serum Concentrations , 2005, Epilepsia.

[52]  D. McClish,et al.  Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[53]  C. Gerlinger,et al.  A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. , 2005, Contraception.

[54]  A. Whittemore,et al.  Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations , 2005, Cancer Epidemiology Biomarkers & Prevention.

[55]  S. Cummings,et al.  Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.

[56]  D. McDonnell.  The molecular determinants of estrogen receptor pharmacology. , 2004, Maturitas.

[57]  A. Girolami,et al.  Effect of Age on Oral Contraceptive-Induced Venous Thrombosis , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[58]  P. Bello,et al.  International Study Group , 2004 .

[59]  D. Herrington,et al.  The effects of smoking on estradiol metabolism. , 2004, Minerva ginecologica.

[60]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[61]  E. Cavalieri,et al.  Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[62]  M. Kulldorff,et al.  Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. , 2003, JAMA.

[63]  P. Crosignani,et al.  The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. , 2003, Contraception.

[64]  A. Mueck,et al.  Smoking, Estradiol Metabolism and Hormone Replacement Therapy , 2003, Arzneimittelforschung.

[65]  F. Couch,et al.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. , 2002, Journal of the National Cancer Institute.

[66]  Katarzyna Kalita,et al.  Estrogen receptor β , 2002 .

[67]  P. Wingo,et al.  Oral contraceptives and the risk of breast cancer. , 2002, The New England journal of medicine.

[68]  D. Archer,et al.  Oral contraceptive efficacy and antibiotic interaction: a myth debunked. , 2002, Journal of the American Academy of Dermatology.

[69]  M. Pike,et al.  Urinary 2-Hydroxyestrone/16α-Hydroxyestrone Ratio and Family History of Breast Cancer in Premenopausal Women , 2002, Breast Cancer Research and Treatment.

[70]  S. Kreiner,et al.  Contraceptives and cerebral thrombosis: a five-year national case-control study. , 2002, Contraception.

[71]  C. Gerlinger,et al.  An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. , 2002, Contraception.

[72]  J. Gustafsson,et al.  Biological Role of Estrogen and Estrogen Receptors , 2002, Critical reviews in biochemistry and molecular biology.

[73]  D. Wallwiener,et al.  Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers. , 2001, Contraception.

[74]  R. Altman,et al.  Drug Interactions Between Oral Contraceptives and Antibiotics , 2001, Obstetrics and gynecology.

[75]  M. Morrell,et al.  Reproductive Dysfunction in Women With Epilepsy: Antiepileptic Drug Effects on Sex-Steroid Hormones , 2001, CNS Spectrums.

[76]  J. Guillebaud,et al.  Medical eligibility criteria for contraceptive use , 2018, Advanced Health Assessment of Women.

[77]  B. Henderson,et al.  Hormones, Genes, and Cancer , 2001 .

[78]  B. Henderson,et al.  Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? , 2001, Cancer research.

[79]  G. Colditz,et al.  Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.

[80]  F. Berrino,et al.  Estrogen Metabolism and Risk of Breast Cancer: a Prospective Study of the 2:16␣-hydroxyestrone Ratio in Premenopausal and Postmenopausal Women , 2022 .

[81]  R. Troisi,et al.  Oral contraceptive use and glucose metabolism in a national sample of women in the united states. , 2000, American journal of obstetrics and gynecology.

[82]  J. Nestler.  Obesity, insulin, sex steroids and ovulation , 2000, International Journal of Obesity.

[83]  C. Delles,et al.  Effects of oral contraceptives on vascular endothelium in premenopausal women. , 2000, American journal of obstetrics and gynecology.

[84]  N. Hanley,et al.  Steroidogenic factor 1 (SF-1) is essential for ovarian development and function , 2000, Molecular and Cellular Endocrinology.

[85]  S. Shapiro.  Bias in the evaluation of low-magnitude associations: an empirical perspective. , 2000, American journal of epidemiology.

[86]  W. Spitzer,et al.  Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. , 2000, Human reproduction.

[87]  M. Rosenberg,et al.  Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations , 1999 .

[88]  K. Bradshaw,et al.  Effect of low-dose oral contraceptives on androgenic markers and acne. , 1999, Contraception.

[89]  R. Young,et al.  Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four month clinical trial. , 1999, American journal of obstetrics and gynecology.

[90]  S. Weiss,et al.  A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss , 1999 .

[91]  A. Miller,et al.  A cohort study of oral contraceptive use and risk of benign breast disease , 1999, International journal of cancer.

[92]  M. Pike,et al.  Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. , 1999, Journal of the National Cancer Institute.

[93]  F. Fruzzetti.  Hemostatic effects of smoking and oral contraceptive use. , 1999, American journal of obstetrics and gynecology.

[94]  W. Bell,et al.  Oral contraceptives and smoking, current considerations: recommendations of a consensus panel. , 1999, American journal of obstetrics and gynecology.

[95]  D. Felsenberg,et al.  A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women , 1999 .

[96]  W. Miller,et al.  Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StARProceedings of Xth International Congress on Hormonal Steroids, Quebec, Canada, 17–21 June 1998. , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[97]  S. Summers,et al.  Steroidogenic Acute Regulatory Protein (StAR) Is A Sterol Transfer Protein* , 1998, The Journal of Biological Chemistry.

[98]  J. Leonard,et al.  Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. , 1998, British journal of clinical pharmacology.

[99]  W. Hop,et al.  The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. , 1998, The Journal of clinical endocrinology and metabolism.

[100]  S. Sidney,et al.  Oral contraceptive use and myocardial infarction. , 1998, Contraception.

[101]  A. Walker,et al.  Newer oral contraceptives and the risk of venous thromboembolism. , 1998, Contraception.

[102]  I. Godsland,et al.  Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. , 1998, Contraception.

[103]  R. Farmer,et al.  The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. , 1998, Contraception.

[104]  B. Bhavnani.  Pharmacokinetics and Pharmacodynamics of Conjugated Equine Estrogens: Chemistry and Metabolism , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[105]  E. Furth,et al.  Localization of the steroidogenic acute regulatory protein in human tissues. , 1997, The Journal of clinical endocrinology and metabolism.

[106]  B. Henderson,et al.  Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? , 1997, Cancer research.

[107]  W. Spitzer,et al.  First-time use of newer oral contraceptives and the risk of venous thromboembolism. , 1997, Contraception.

[108]  W. Spitzer,et al.  The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. , 1997, Contraception.

[109]  J. Sparano,et al.  Urinary estrogen metabolites and breast cancer: a case-control study. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[110]  M. Pike,et al.  A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. , 1997, Environmental health perspectives.

[111]  J. Manson,et al.  A Prospective Study of Oral Contraceptives and NIDDM Among U.S. Women , 1997, Diabetes Care.

[112]  J. Mant,et al.  Combined oral contraceptives and liver disease. , 1997, Contraception.

[113]  R. Farmer,et al.  Population-based study of risk of venous thromboembolism associated with various oral contraceptives , 1997, The Lancet.

[114]  T. Dieben,et al.  The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. , 1996, Contraception.

[115]  M. Osborne,et al.  2-hydroxyestrone: the 'good' estrogen. , 1996, The Journal of endocrinology.

[116]  J. Manson,et al.  Prospective study of oral contraceptives and hypertension among women in the United States. , 1996, Circulation.

[117]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.

[118]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[119]  A. Gougeon.  Regulation of ovarian follicular development in primates: facts and hypotheses. , 1996, Endocrine reviews.

[120]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[121]  P. Ganz,et al.  Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.

[122]  J. Goldzieher,et al.  Pharmacology of the Contraceptive Steroids , 1994 .

[123]  P. Fioretti,et al.  Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. , 1994, Contraception.

[124]  Y. Ito,et al.  Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. , 1994, Endocrine reviews.

[125]  P. Croft,et al.  Oral Contraception and Stroke Evidence From the Royal College of General Practitioners' Oral Contraception Study , 1994, Stroke.

[126]  C. Gansau,et al.  Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol. , 1993, Arzneimittel-Forschung.

[127]  A. Decherney,et al.  EVALUATION OF A NEW GENERATION OF ORAL CONTRACEPTIVES , 1993, Obstetrics and gynecology.

[128]  B. Newman,et al.  Effect of four combined oral contraceptives on blood pressure in the pill-free interval. , 1993, Contraception.

[129]  D. Back,et al.  Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol. , 1993, Contraception.

[130]  D. Roy,et al.  The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites. , 1993, Endocrinology.

[131]  S. Shapiro,et al.  A case-control study of the risk of breast cancer in relation to oral contraceptive use. , 1992, American journal of epidemiology.

[132]  C. Kitchens,et al.  Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial. , 1992, American journal of obstetrics and gynecology.

[133]  T. Rohan,et al.  Oral contraceptives and risk of benign proliferative epithelial disorders of the breast , 1992, International journal of cancer.

[134]  A. LaCroix,et al.  Smoking and mortality among older men and women in three communities. , 1991, The New England journal of medicine.

[135]  I. Godsland,et al.  The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. , 1990, The New England journal of medicine.

[136]  J. Li,et al.  Estrogen carcinogenesis in hamster tissues: a critical review. , 1990, Endocrine reviews.

[137]  C. Christiansen,et al.  Estrogens, bone loss and preservation , 1990, Osteoporosis International.

[138]  L. Havekes,et al.  Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism. , 1990, American journal of obstetrics and gynecology.

[139]  U. Gaspard,et al.  Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. , 1990, American journal of obstetrics and gynecology.

[140]  H. Rekers,et al.  Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations. , 1990, American journal of obstetrics and gynecology.

[141]  J. Jespersen,et al.  Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. , 1990, American journal of obstetrics and gynecology.

[142]  W. Kuhnz,et al.  Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum. , 1990, Journal of steroid biochemistry.

[143]  D. Yeates,et al.  Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. , 1989 .

[144]  A. Gotto,et al.  The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. , 1989, American journal of obstetrics and gynecology.

[145]  J. Goldzieher,et al.  Pharmacokinetics of three bioequivalent norethindrone/mestranol-50ug and three norethindrone/ethinyl estradiol-35ug oc formulations: Are “low-dose” pills really lower? , 1989 .

[146]  R. P. Myers,et al.  Human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase: purification from mitochondria and kinetic profiles, biophysical characterization of the purified mitochondrial and microsomal enzymes. , 1989, Journal of steroid biochemistry.

[147]  J. Goldzieher.  Pharmacology of contraceptive steroids: a brief review. , 1989, American journal of obstetrics and gynecology.

[148]  E. Feldman,et al.  Lipid and lipoprotein changes in women taking low‐dose, triphasic oral contraceptives: A controlled, comparative, 12‐month clinical trial , 1989, American journal of obstetrics and gynecology.

[149]  P. Croft,et al.  Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. , 1989, BMJ.

[150]  J. Fishman,et al.  Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[151]  B. Bhavnani.  The saga of the ring B unsaturated equine estrogens. , 1988, Endocrine reviews.

[152]  P. Ylöstalo,et al.  New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women. , 1988, Maturitas.

[153]  Kenneth G. Mann,et al.  Evidence of estrogen receptors in normal human osteoblast-like cells , 1988 .

[154]  I. Godsland,et al.  Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins. , 1988, American journal of obstetrics and gynecology.

[155]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[156]  A. Kimball,et al.  Lipid and Lipoprotein Changes Associated With Oral Contraceptive Use: A Randomized Clinical Trial , 1988, Obstetrics and Gynecology.

[157]  W. Schubert,et al.  Ovulation Inhibition with 17β‐Estradiol Cyclo‐Octyl Acetate and Desogestrel , 1987 .

[158]  C. Kelleher,et al.  Blood pressure alters during the normal menstrual cycle , 1986 .

[159]  D. Mant,et al.  Oral contraceptives and venous thromboembolism: findings in a large prospective study. , 1986, British medical journal.

[160]  A. Gougeon.  Dynamics of follicular growth in the human: a model from preliminary results. , 1986, Human reproduction.

[161]  J. Fishman,et al.  Interaction of histones with estrogens. Covalent adduct formation with 16 alpha-hydroxyestrone. , 1985, Biochemistry.

[162]  C. Longcope,et al.  The metabolism of estradiol; oral compared to intravenous administration. , 1985, Journal of steroid biochemistry.

[163]  B. Bhavnani,et al.  Transport of equine estrogens: binding of conjugated and unconjugated equine estrogens with human serum proteins. , 1985, The Journal of clinical endocrinology and metabolism.

[164]  H. Bradlow,et al.  Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[165]  S. Shapiro,et al.  Myocardial infarction and cigarette smoking in women younger than 50 years of age. , 1985, JAMA.

[166]  B. Jugdutt,et al.  Myocardial infarction, oral contraception, cigarette smoking, and coronary artery spasm in young women. , 1983, American heart journal.

[167]  P. Wahl,et al.  Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. , 1983, The New England journal of medicine.

[168]  B. Düsterberg,et al.  Pharmacokinetic and pharmacological features of oestradiol valerate. , 1982, Maturitas.

[169]  D. Mishell,et al.  Comparison of pharmacodynamic properties of various estrogen formulations. , 1982, American journal of obstetrics and gynecology.

[170]  E. Simpson,et al.  The Role of Lipoproteins in the Regulation of Progesterone Secretion by the Human Corpus Luteum , 1982, Fertility and sterility.

[171]  K. Anderson,et al.  Abnormal oxidative metabolism of estradiol in women with breast cancer. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[172]  T. Meade.  Oral contraceptives, clotting factors, and thrombosis. , 1982, American journal of obstetrics and gynecology.

[173]  A. Vermeulen,et al.  Plasma levels of ethinylestradiol (EE) during cyclic treatment with combined oral contraceptives. , 1981, Contraception.

[174]  R. Dickson,et al.  17 Alpha-ethinyl estradiol is more potent than estradiol in receptor interactions with isolated hepatic parenchymal cells. , 1981, Endocrinology.

[175]  L. Brinton,et al.  Risk factors for benign breast disease. , 1981, American journal of epidemiology.

[176]  D. G. Dale.  Monographs on Endocrinology , 1981 .

[177]  R. Parker,et al.  A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens , 1980 .

[178]  H. Adlercreutz,et al.  Biliary excretion and intestinal metabolism of progesterone and estrogens in man. , 1980, Journal of steroid biochemistry.

[179]  L. Svanberg,et al.  CLINICAL TRIAL OF A NEW ORAL CONTRACEPTIVE PILL CONTAINING THE NATURAL OESTROGEN 17β‐OESTRADIOL , 1979 .

[180]  H. Adlercreutz,et al.  Steroid absorption and enterohepatic recycling. , 1979, Contraception.

[181]  E. Bostofte,et al.  NATURAL ŒSTROGENS FOR ORAL CONTRACEPTION , 1979, The Lancet.

[182]  D. Killinger,et al.  The interconversion and aromatization of androgens by human adipose tissue. , 1979, Journal of steroid biochemistry.

[183]  I. Godsland,et al.  COMPARISON OF EFFECTS OF DIFFERENT COMBINED ORAL-CONTRACEPTIVE FORMULATIONS ON CARBOHYDRATE AND LIPID METABOLISM , 1979, The Lancet.

[184]  J. Wilson,et al.  Aromatization of androstenedione by cultured human fibroblasts. , 1976, The Journal of clinical endocrinology and metabolism.

[185]  Chung-Hsiu Wu,et al.  Free and Protein-Bound Plasma Estradiol-17β During the Menstrual Cycle , 1976 .

[186]  H. Wendt,et al.  Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB). , 1976, Contraception.

[187]  D. Gordon.  WOODPECKERS' TONGUES , 1976, The Lancet.

[188]  P. Siiteri,et al.  Plasma Precursors of Estrogen , 1976 .

[189]  K. Ryan,et al.  Aromatization of androgens by human abdominal and breast fat tissue. , 1975, The Journal of clinical endocrinology and metabolism.

[190]  J. Wilson,et al.  Aromatization of androstenedione by isolated human hairs. , 1975, The Journal of clinical endocrinology and metabolism.

[191]  David C. Anderson,et al.  SEX‐HORMONE‐BINDING GLOBULIN , 1974, Clinical endocrinology.

[192]  J. Leeton.  The Relationship of Oral Contraception to Depressive Symptoms , 1973, The Australian & New Zealand journal of obstetrics & gynaecology.

[193]  K. Fotherby,et al.  Metabolism of ethynyloestradiol in man. , 1972, The Journal of endocrinology.

[194]  A. Schindler,et al.  CONVERSION OF ANDROSTENEDIONE TO ESTRONE BY HUMAN FAT TISSUE , 1972 .

[195]  B. Macmahon,et al.  Menopause and breast cancer risk. , 1972, Journal of the National Cancer Institute.

[196]  F. Naftolin,et al.  AROMATIZATION OF ANDROSTENEDIONE BY THE DIENCEPHALON1 , 1971 .

[197]  B. Somerville.  The role of progesterone in menstrual migraine , 1971, Neurology.

[198]  M. Oliver,et al.  Oral Contraceptives and Myocardial Infarction , 1970, British medical journal.

[199]  A. Meli,et al.  Fate of ingested radiolabeled ethynylestradiol and its 3-cyclopentyl ether in patients with bile fistulas. , 1969, The Journal of clinical endocrinology and metabolism.

[200]  D. Baird,et al.  Concentration of unconjugated estrone and estradiol in peripheral plasma in nonpregnant women throughout the menstrual cycle, castrate and postmenopausal women and in men. , 1969, The Journal of clinical endocrinology and metabolism.

[201]  K. Ryan,et al.  Steroid formation by isolated and recombined ovarian granulosa and tehcal cells. , 1968, The Journal of clinical endocrinology and metabolism.

[202]  H. Waine.  Management of the rheumatoid patient. , 1963, Arthritis and rheumatism.

[203]  K. Ryan,et al.  Biogenesis of estrogens by the human ovary. I. Conversion of acetate-1-C-14 to estrone and estradiol. , 1961, The Journal of biological chemistry.

[204]  F. Plum.  Handbook of Physiology. , 1960 .

[205]  A. Sandberg,et al.  Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C14-estrone and C14-estradiol in women. , 1957, The Journal of clinical investigation.

[206]  A. Sandberg,et al.  Studies on phenolic steroids in human subjects. , 1956, Archives of biochemistry and biophysics.

[207]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[208]  K. Culwell,et al.  The use of hormonal contraception among women taking anticonvulsant therapy. , 2011, Contraception.

[209]  U. Mellinger,et al.  Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive , 2011, Clinical drug investigation.

[210]  J. Bitzer,et al.  Review of clinical experience with estradiol in combined oral contraceptives. , 2010, Contraception.

[211]  E. Adashi,et al.  The Physiology and Pathology of the Female Reproductive Axis , 2007 .

[212]  I. Fentiman,et al.  Epidemiology and endocrinology of benign breast disease , 2005, Breast Cancer Research and Treatment.

[213]  D. Mishell,et al.  Effect of oral contraceptives containing 20 and 35 μg ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers , 1999 .

[214]  M. C. Leske,et al.  Breast cancer and hormonal contraceptives: further results , 1996 .

[215]  P. Ylöstalo,et al.  Oral contraceptive containing natural estradiol for premenopausal women. , 1995, Maturitas.

[216]  A. Teichmann.  Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. , 1995, International journal of fertility and menopausal studies.

[217]  J. Donnez,et al.  Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives. , 1995, Contraception.

[218]  H. Zimmermann,et al.  Pharmacokinetics of Exogenous Natural and Synthetic Estrogens and Antiestrogens , 1993 .

[219]  F. Lundin,et al.  Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. , 1991, American journal of epidemiology.

[220]  F. Guengerich.  Metabolism of 17 α-ethynylestradiol in humans , 1990 .

[221]  D. Back,et al.  Interindividual variation in the metabolism of ethynylestradiol. , 1989, Pharmacology & therapeutics.

[222]  P. Siiteri.  Adipose tissue as a source of hormones. , 1987, The American journal of clinical nutrition.

[223]  C. Bulpitt,et al.  The effect of the contraceptive pill on blood pressure: a randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary. , 1986, Contraception.

[224]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[225]  M. Hümpel,et al.  Pharmacokinetics and biotransformation of estradiol valerate in ovariectomized women. , 1985, Hormone research.

[226]  Leon Speroff,et al.  Clinical gynecologic endocrinology and infertility , 1983 .

[227]  P. Lichtlen,et al.  Coronary atherosclerosis and myocardial infarction in young women--role of oral contraceptives. , 1983, European heart journal.

[228]  R. W. Kuhn,et al.  The serum transport of steroid hormones. , 1982, Recent progress in hormone research.

[229]  K. Fotherby.  Pharmacokinetics of ethynyloestradiol in humans. , 1982, Methods and findings in experimental and clinical pharmacology.

[230]  W. Pardridge,et al.  Transport of protein-bound hormones into tissues in vivo. , 1981, Endocrine reviews.

[231]  M. Christensen,et al.  Bioavailability of Four Oestradiol Suspensions with Different Particle-Sizes - In Vivo/In Vitro Correlation , 1981 .

[232]  E. Bostofte,et al.  Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation. , 1981, Acta obstetricia et gynecologica Scandinavica.

[233]  V. Ernster.  The epidemiology of benign breast disease. , 1981, Epidemiologic reviews.

[234]  E. Knobil,et al.  The neuroendocrine control of the menstrual cycle. , 1980, Recent progress in hormone research.

[235]  C. Longcope,et al.  Aromatization of androgens by muscle and adipose tissue in vivo. , 1978, The Journal of clinical endocrinology and metabolism.

[236]  P. Siiteri,et al.  Plasma precursors of estrogen. III. Conversion of plasma dehydroisoandrosterone to estrogen in young nonpregnant women. , 1976, Gynecologic investigation.

[237]  Ulrich Westphal,et al.  Steroid-Protein Interactions , 1971, Monographs on Endocrinology.

[238]  T. Gallagher,et al.  Intermediates in the transformation of oral estradiol. , 1969, The Journal of clinical endocrinology and metabolism.

[239]  C. Longcope,et al.  Metabolic clearance rates and interconversions of estrone and 17beta-estradiol in normal males and females. , 1968, The Journal of clinical investigation.

[240]  E. Gurpide,et al.  STUDIES ON THE SECRETION AND INTERCONVERSION OF THE ANDROGENS. , 1963, Recent progress in hormone research.

[241]  L. Ma.  Appearance of mammary cancers in male mice subjected to folliculin injections , 1932 .